Ladenburg downgraded Evaxion Biotech to Neutral from Buy with no price target after the company reported Q3 financials and business updates. The “major news” from the earnings update was that Evaxion is currently waiting for a strategic partner to advance any program into the clinic, says the analyst, who attributes a lack of clear strategic plans for the time being for stepping to the sidelines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EVAX:
- Evaxion Announces Business Update and Third Quarter 2023 Financial Results
- Evaxion Biotech Announces Private Placement Financing
- Evaxion Biotech prices 9.73M shares at 54.4c in private placement
- Evaxion Biotech announces presentation of novel vaccine concept
- Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
